Join to access to all OVN content. Join for Free
An Unexpected Journey From Novice MSL to Global Medical Excellence Leader with Tonya Johnson
Medical Science Liaison networking and mentorship Key Opinion Leader relationships career development strategies emotional intelligence for MSLs

An Unexpected Journey From Novice MSL to Global Medical Excellence Leader with Tonya Johnson


Share This Article


Summary

In this episode, Tom Caravela welcomes Dr. Tanya Johnson, who shares her inspiring journey from Newark to becoming a Medical Science Liaison (MSL). Tanya emphasizes the importance of networking and mentorship in the MSL field and offers insights into building and maintaining strong Key Opinion Leader (KOL) relationships. She discusses career development strategies, the roles of mentors and sponsors, and proactive career management. Tanya also explores the global medical excellence leader role and highlights key skills and emotional intelligence necessary for MSLs today. The episode concludes with Tanya's thoughts on future directions for MSLs.

My guest today is Dr. Tonya Johnson, she was a former Global Medical leader of MSL Excellence. We discuss TJ’s trek from no experience to Global Medical Affairs leader.

In this episode we discuss:

  • Who is Tonya
  • Transitioning to the industry
  • The concept of mentors and sponsors
  • The approach to finding a mentor or a sponsor
  • Finding mentors
  • What is Global Medical Excellence
  • What skills are mandatory for the MSLs of today

Click for Source
Medical Science Liaison, networking and mentorship, Key Opinion Leader relationships, career development strategies, emotional intelligence for MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN